Technology | Vascular Closure Devices | December 14, 2017

Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.

First commercial cases demonstrated excellent time to hemostasis in a variety of clinical situations

Vasorum Launches Celt ACD Second-Generation Vascular Closure Device in the U.S.

December 14, 2017 — Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt ACD device to its range following U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement. Celt ACD is indicated for arterial puncture closure in both diagnostic and interventional cardiology and radiology patients. Vasorum said the device offers excellent time to hemostasis in a wide variety of clinical situations. The second-generation Celt ACD devices now available in both the United States and Europe have a new improved delivery system which has been designed to enhance the user experience during deployment.

The first commercial cases in the U.S. have been carried out by Shing-Chiu Wong, M.D., professor of medicine at Weill Cornell Medicine in New York. Based on his use, Wong commented that the "Celt ACD range of closure devices are addressing the clear need for quicker and more efficient methods of increasing patient throughput in healthcare facilities, and they provide doctors and patients with a solution which can efficiently manage arterial closure following vascular procedures."

Clinical cases have also been carried out by Richard Kovach, M.D., division director, interventional cardiology and medical director, cardiac catheterization laboratory at Deborah Heart and Lung, Browns Mills, N.J. Kovach commented that he "was impressed with the performance of Celt ACD in patients with severe arterial disease undergoing complex interventional procedures." Additionally, he believes that "Celt ACD has the potential to become the workhorse closure device in cath labs."

There are currently over 8 million catheter procedures performed annually, which support an estimated $1 billion femoral artery closure device market. The number of procedures is expected to exceed 10 million by 2020. In addition to interventional cardiology procedures, the market growth is being driven by an increasing number of peripheral vascular, neuro-vascular and other catheter procedures which demand more patient-friendly devices and more efficient patient discharge from hospitals.         

For more information: www.vasorum.ie

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...